Breaking Finance News

A statement released earlier today by Commerzbank AG about RHOEN-KLINIKUM (ETR:RHK) bumps the target price to 31.00EUR

Commerzbank AG upped the price target of RHOEN-KLINIKUM (ETR:RHK) to 31.00EUR reporting a possible upside of 0.17%.

Previously on 10/7/2016, Commerzbank AG reported on RHOEN-KLINIKUM (ETR:RHK) increased the target price from 0.00EUR to 31.00EUR. At the time, this indicated a possible upside of 0.17%.

Just yesterday RHOEN-KLINIKUM (ETR:RHK) traded 0.00% even at 26.52EUR. RHOEN-KLINIKUM’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 0 shares of RHK traded hands, down from an avg. volume of 0

Performance Chart


With a total market value of 0 EUR, RHOEN-KLINIKUM has with a 52 week low of 0.00EUR and a 52 week high of 0.00EUR .


Rhoen Klinikum AG is a Germany-based provider of health care services. It operates acute hospitals, medical care centers and rehabilitation hospitals across Germany: six clinics on Campus Bad Neustadt, including the Cardiovascular Clinic, the Frankenklinik for the Rehabilitation of Cardiovascular Patients, the Clinic for Hand Surgery, the Neurological Clinic, the Psychosomatic Clinic and the Saaletalklinik with two additional addiction therapy facilities; Klinikum Frankfurt (Oder) comprises clinics, psychiatric outpatient institutions and day clinics; University Hospital Giessen and Marburg (UKGM) offers medical services, modern diagnostics and comprehensive therapy in various areas, including ophthalmology, trauma surgery and dentistry, and Zentralklinik Bad Berka provides health care services to patients with thoracic, pulmonary and vascular diseases, tumors, neurological conditions, and diseases of the spinal column, joints and heart, among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *